Portal de Periódicos da CAPES

Clinical Course of Ovarian Cancer Patients Under Repeated Stimulation of HAMA Using MAb OC125 and B43.13

1993; Mary Ann Liebert, Inc.; Volume: 12; Issue: 5 Linguagem: Inglês

10.1089/hyb.1993.12.583

2168-7897

Richard P. Baum, A.A. Noujaim, Andreea A. Nanci, Volker Moebus, A. Hertel, A. Niesen, B. Donnerstag, T.R. Sykes, G. R. Boniface, G. Hör,

CAR-T cell therapy research

HybridomaVol. 12, No. 5 Clinical Course of Ovarian Cancer Patients Under Repeated Stimulation of HAMA Using MAb OC125 and B43.13R.P. BAUM, A.A. NOUJAIM, A. NANCI, V. MOEBUS, A. HERTEL, A. NIESEN, B. DONNERSTAG, T. SYKES, G. BONIFACE, and G. HÖRR.P. BAUM, A.A. NOUJAIM, A. NANCI, V. MOEBUS, A. HERTEL, A. NIESEN, B. DONNERSTAG, T. SYKES, G. BONIFACE, and G. HÖRPublished Online:24 Apr 2009https://doi.org/10.1089/hyb.1993.12.583AboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail FiguresReferencesRelatedDetailsCited byFront-line chemo-immunotherapy for treating epithelial ovarian cancer: Part I CA125 and anti-CA125Taiwanese Journal of Obstetrics and Gynecology, Vol. 62, No. 6Oregovomab: an investigational agent for the treatment of advanced ovarian cancer11 January 2021 | Expert Opinion on Investigational Drugs, Vol. 30, No. 2Pre-existing antitherapeutic antibodies against the Fc region of the hu14.18K322A mAb are associated with outcome in patients with relapsed neuroblastoma12 March 2020 | Journal for ImmunoTherapy of Cancer, Vol. 8, No. 1MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress29 May 2014 | Molecular Cancer, Vol. 13, No. 1Immuno-PET of epithelial ovarian cancer: harnessing the potential of CA125 for non-invasive imaging12 November 2014 | EJNMMI Research, Vol. 4, No. 1Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival—a substudy of the MIMOSA trial21 June 2014 | Cancer Immunology, Immunotherapy, Vol. 63, No. 10Monoclonal antibodies therapies for ovarian cancer4 February 2013 | Expert Opinion on Biological Therapy, Vol. 13, No. 5Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancerImmunotherapy, Vol. 3, No. 2Monoclonal Antibodies in Gynecological Cancer: A Critical Point of ViewClinical and Developmental Immunology, Vol. 2011The detection, treatment, and biology of epithelial ovarian cancer29 March 2010 | Journal of Ovarian Research, Vol. 3, No. 1Use of monoclonal antibodies in the treatment of ovarian cancerCurrent Opinion in Obstetrics & Gynecology, Vol. 22, No. 1Consolidation Therapy in Ovarian Cancer: A Clinical Update1 November 2009 | International Journal of Gynecologic Cancer, Vol. 19, No. Suppl 2Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancerGynecologic Oncology, Vol. 113, No. 3New therapeutic agents in ovarian cancerCurrent Opinion in Obstetrics & Gynecology, Vol. 21, No. 1REVIEW ARTICLE: Harnessing the Immune System for Ovarian Cancer Therapy12 December 2007 | American Journal of Reproductive Immunology, Vol. 59, No. 1CA125 in ovarian cancerBiomarkers in Medicine, Vol. 1, No. 4Immunologic Approaches to Ovarian Cancer TreatmentJournal of Clinical Oncology, Vol. 25, No. 20Design of a bifunctional fusion protein for ovarian cancer drug delivery: Single-chain anti-CA125 core-streptavidin fusion proteinEuropean Journal of Pharmaceutics and Biopharmaceutics, Vol. 65, No. 3A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancerInternational Journal of Gynecological Cancer, Vol. 15, No. 6Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancerAmerican Journal of Obstetrics and Gynecology, Vol. 189, No. 1Specific Keynote: Immunological Therapy for Ovarian CancerGynecologic Oncology, Vol. 88, No. 1Immunotherapy of Ovarian CancerInduction of CA125-Specific B and T Cell Responses in Patients Injected with MAb-B43.13—Evidence for Antibody-Mediated Antigen-Processing and Presentation of CA125 in Vivo Antoine A. Noujaim, Birgit C. Schultes, Richard P. Baum, and Ragupathy Madiyalakan5 July 2004 | Cancer Biotherapy & Radiopharmaceuticals, Vol. 16, No. 3Development and Characterization of a Bispecific Single-Chain Antibody Directed Against T Cells and Ovarian Carcinoma Jitra Kriangkum, Biwen Xu, Christian Gervais, Denis Paquette, Frederik A. Jacobs, Luis Martin, and Mavanur R. Suresh7 July 2004 | Hybridoma, Vol. 19, No. 1Immunotherapy of Human Ovarian Carcinoma with OVAREXTM MAb-B43.13 in a Human-PBL-SCID/BG Mouse Model BIRGIT C. SCHULTES, CHENGSHENG ZHANG, LANNY Y. XUE, ANTOINE A. NOUJAIM, and RAGUPATHI MADIYALAKAN25 April 2009 | Hybridoma, Vol. 18, No. 1Immunophotodynamic therapy: Current developments and future prospectsDrug Development Research, Vol. 42, No. 3-4Generation of Human Monoclonal Anti-idiotypic Antibodies with Specificity to the Murine Monoclonal Anti-CA 125 Antibody B43.1316 April 2018 | The International Journal of Biological Markers, Vol. 11, No. 4Evaluation of Tumor Immunity in Patients with Ovarian Cancer after Immunoscintigraphy in a Long-Term Follow-up B. DONNERSTAG, R.P. BAUM, J.B. OLTROGGE, K. HENZEL, L. TRÄGER, and G. HÖR24 April 2009 | Hybridoma, Vol. 14, No. 2Antiidiotype Induction Therapy: Evidence for the Induction of Immune Response through the Idiotype Network in Patients with Ovarian Cancer after Administration of Anti-CA 125 Murine Monoclonal Antibody B43.13 R. MADIYALAKAN, T.R. SYKES, S. DHARAMPAUL, C.J. SYKES, R.P. BAUM, G. HÖR, and A.A. NOUJAIM24 April 2009 | Hybridoma, Vol. 14, No. 2Prospects for an Immunological Approach to Therapy of Ovarian Cancer30 October 2012 | Clinical Immunotherapeutics, Vol. 2, No. 6 Volume 12Issue 5Oct 1993 To cite this article:R.P. BAUM, A.A. NOUJAIM, A. NANCI, V. MOEBUS, A. HERTEL, A. NIESEN, B. DONNERSTAG, T. SYKES, G. BONIFACE, and G. HÖR.Clinical Course of Ovarian Cancer Patients Under Repeated Stimulation of HAMA Using MAb OC125 and B43.13.Hybridoma.Oct 1993.583-589.http://doi.org/10.1089/hyb.1993.12.583Published in Volume: 12 Issue 5: April 24, 2009PDF download